A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of AZD8931 In Combination with Anastrozole, Compared to Anastrozole alone, in Post-menopausal Women With Hormone Receptor-positive, Endocrine Therapy-naive, Locally-advanced or Metastatic Breast Cancer. - MINT

Trial Profile

A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of AZD8931 In Combination with Anastrozole, Compared to Anastrozole alone, in Post-menopausal Women With Hormone Receptor-positive, Endocrine Therapy-naive, Locally-advanced or Metastatic Breast Cancer. - MINT

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2017

At a glance

  • Drugs Sapitinib (Primary) ; Anastrozole
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms MINT
  • Sponsors AstraZeneca
  • Most Recent Events

    • 04 Jun 2013 Interim results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 16 Nov 2012 Primary endpoint 'Progression-free-survival-duration' has not been met.
    • 16 Nov 2012 Planned end date changed from 1 Aug 2015 to 1 Mar 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top